SCHEMBL2321355

SCHEMBL2321355

NNC(=O)CSc1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.59
HSD17B10 Q99714 3/20 0.58
ALDH1A1 P00352 3/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
MITF O75030 1/20 0.58
TSHR P16473 1/20 0.58
SDCBP O00560 1/20 0.55
SDC2 P34741 1/20 0.55
HTT P42858 2/20 0.54
TDP1 Q9NUW8 1/20 0.52
TEAD1 P28347 1/20 0.51
YAP1 P46937 1/20 0.51
TEAD4 Q15561 1/20 0.51
TEAD2 Q15562 1/20 0.51
CYP1A2 P05177 2/20 0.51
MAPT P10636 2/20 0.51
CASP1 P29466 1/20 0.51
GAA P10253 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15426813 0.85 ALDH1A1 (0.50) HPGDHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL5656305 0.83 RAB9A (0.49) HPGDHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL11870523 0.81 SMN1; SMN2 (0.65) HPGDALDH1A1MEN1KMT2ATDP1
SCHEMBL11870623 0.81 HPGD (0.61) HPGDHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL28117136 0.81 ALDH1A1 (0.58) ALDH1A1MEN1KMT2AHTTTDP1
SCHEMBL10717383 0.81 CYP1A2 (0.68) HPGDHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL11867961 0.81 ALDH1A1 (0.48) HPGDHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL11872394 0.81 HPGD (0.51) HPGDHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL1224206 0.80 TRPM5 (0.50) HPGDHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL11863116 0.79 ALDH1A1 (0.49) HPGDALDH1A1MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065962-A1 Compounds For Use In The Treatment Of Diseases INOXIA LIFESCIENCES GMBH (AT) 2013-03-14 US claimed
CN-102858329-A Compounds for the treatment of diseases PLANTA NATURSTOFFE VERTRIEBSGES M B H 2013-01-02 CN claimed
EP-2528595-A1 COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES Inoxia Lifesciences GmbH (AT) 2012-12-05 EP claimed
WO-2011091461-A1 COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES PLANTA NATURSTOFFE VERTRIEBSGES.M.B.H. (AT) 2011-08-04 WO claimed
CN-106632129-B The double thioether analog derivative, preparation method and application of (thiophene) diazole are disliked containing 1,3,4- 贵州大学 2019-06-07 CN disclosed
CN-106167472-B A kind of 2,5- substituent groups -1,3,4- oxadiazole double thioethers analog derivative, preparation method and application 贵州大学 2018-07-27 CN disclosed
CN-106632129-A Disulfide derivative containing 1,3,4-oxa(thia)diazole and preparation method and application of derivative 贵州大学 2017-05-10 CN disclosed
CN-106167472-A A kind of 2,5 substituent group 1,3,4 diazole thioether analog derivatives, its preparation method and application 贵州大学 2016-11-30 CN disclosed
EP-2965755-A1 COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES Inoxia Lifesciences GmbH (AT) 2016-01-13 EP disclosed
EP-2965755-A1 COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES Inoxia Lifesciences GmbH (AT) 2016-01-13 EP disclosed
CN-104958286-A Compounds for use in the treatment of diseases INOXIA LIFESCIENCES GMBH 2015-10-07 CN disclosed
CN-102858329-B Compounds for the treatment of diseases INOXIA LIFESCIENCES GMBH 2015-06-17 CN disclosed
US-20130065962-A1 Compounds For Use In The Treatment Of Diseases INOXIA LIFESCIENCES GMBH (AT) 2013-03-14 US disclosed
US-20130065962-A1 Compounds For Use In The Treatment Of Diseases INOXIA LIFESCIENCES GMBH (AT) 2013-03-14 US disclosed
US-20130065962-A1 Compounds For Use In The Treatment Of Diseases INOXIA LIFESCIENCES GMBH (AT) 2013-03-14 US disclosed
CN-102858329-A Compounds for the treatment of diseases PLANTA NATURSTOFFE VERTRIEBSGES M B H 2013-01-02 CN disclosed
EP-2528595-A1 COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES Inoxia Lifesciences GmbH (AT) 2012-12-05 EP disclosed
WO-2011091461-A1 COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES PLANTA NATURSTOFFE VERTRIEBSGES.M.B.H. (AT) 2011-08-04 WO disclosed
US-3972905-A FUNGICIDE BAYER AKTIENGESELLSCHAFT (DT) 1976-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065962-A1 Compounds For Use In The Treatment Of Diseases SLC10A1, CYP27A1, OAT HPGD 401/4885HSD17B10 458/4885ALDH1A1 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.